Nanding, Norseda P.
HRN: 26-85-39 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/10/2025
CO-AMOXICLAV 625MG (TAB)
04/10/2025
04/16/2025
PO
500mg
BID
Nsvd 3rd Degree
Waiting Final Action
Indication: Prophylaxis Type of Infection: Prophylaxis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes